This article needs additional citations for verification. (December 2010) |
Clinical data | |
---|---|
Other names | Selanc; L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-Proline |
Routes of administration | Nasal muscosa, IV |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C33H57N11O9 |
Molar mass | 751.887 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Selank (Russian: Cеланк) is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of human tuftsin.